Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 8;53(7):2836-42.
doi: 10.1021/jm100135g.

Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization

Affiliations

Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization

Kaleeckal G Harikumar et al. J Med Chem. .

Abstract

CCK(2) receptor antagonists potentiate pain relief by MOP receptor agonists. In an attempt to enhance this effect, we prepared bivalent ligands incorporating CCK(2) receptor antagonist and MOP receptor agonist pharmacophores. (9) Ligands with 16- to 22-atom spacers could simultaneously bind both receptors but provided no advantage in activity over individual ligands. We now examine the effect of these ligands on receptor internalization as a mechanism of receptor regulation. We prepared CHO cell lines expressing nonfluorescent halves (YN and YC) of yellow fluorescent protein attached to each receptor. Spatial approximation of constructs was needed to yield fluorescence. Monovalent MOP agonist 1 signaled normally and internalized the MOP receptor. Monovalent CCK(2) antagonist 2 did not stimulate receptor internalization. In the dual receptor-bearing cells, bivalent ligands 3a-c capable of simultaneously binding both receptors resulted in cell surface fluorescence and internalization of the fluorescent complex in a time- and temperature-dependent manner. Bivalent ligand 4 with spacer too short to occupy both receptors simultaneously yielded no signal. Receptor tethering with appropriate bivalent ligands can down-regulate signaling by moving a nonactivated receptor into the endocytic pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of monovalent and bivalent ligands. Shown are the chemical structures of the monovalent ligands with MOP (1) or CCK2 (2) receptor pharmacophores and bivalent ligands (3ac, 4) containing both pharmacophores.
Figure 2
Figure 2
Bimolecular fluorescence complementation. Shown are representative epifluorescence images of COS cells expressing the indicated receptor constructs. Microscopic images show the effective physical complementation of YN-tagged receptor and YC-tagged receptor to yield fluorescent YFP. These observations support the previous reports of constitutive homo-oligomerization of the CCK2 and MOP receptors. No YFP fluorescence complementation was observed when the complementarily tagged CCK2 and MOP receptors were coexpressed, again supporting the previous BRET study showing absence of hetero-oligomerization. Scale bar: 25 μm.
Figure 3
Figure 3
Receptor expression on CHO-CCK2-YN/MOP-YC cells. Shown are concentration–response curves in intact cells, which represent compound 5 competing for CCK radioligand binding (A) and compound 6 inhibiting forskolin-stimulated cAMP responses (B). Data are expressed as the mean ± SEM of values from three to four independent experiments performed in duplicate.
Figure 4
Figure 4
Ligand-dependent internalization of MOP receptors and CCK2 receptors on CHO cell lines. Shown are representative epifluorescence microscopic images illustrating time-dependent internalization of YFP-tagged MOP receptor exposed to compound 6 (A) and absence of internalization of the YFP-tagged CCK2 receptor exposed to compound 5 (B). In contrast, CCK stimulation of the CCK2 receptor is known to stimulate receptor internalization. Also shown are similar images from these cells stimulated with the monovalent MOP receptor agonist (compound 1) (C) and monovalent CCK2 receptor antagonist (compound 2) (D). Scale bar: 25 μm.
Figure 5
Figure 5
Bivalent ligand-induced fluorescence complementation in CHO-CCK2-YN/MOP-YC cells. Shown are representative phase contrast and epifluorescence microscopic images of CHO-CCK2-YN/MOP-YC cells exposed to various ligands for 90 min at 4 °C. Compounds 1 and 2, representing monovalent ligands, were unable to form intact fluorescent YFP. Compounds 3a, 3b, and 3c, representing bivalent ligands with adequate length spacers to bind to both receptors simultaneously, were able to form intact fluorescent YFP on the cell surface under these conditions. Compound 4, with the short nine-atom spacer, and the bivalent peptidyl ligand (Tyr-D-Ala-Gly-D-Trp-NMe-Nle-Asp-Phe-NH2, compound 7) were not able to form fluorescent YFP. Scale bar: 25 μm.
Figure 6
Figure 6
Time-dependent internalization of CCK2 and MOP receptors in CHO-CCK2-YN/MOP-YC cells. Bivalent ligands, compounds 3a, 3b, and 3c, that were able to elicit fluorescent YFP by complementation of the tags on the CHO-CCK2-YN/MOP-YC cells also stimulated the time-dependent internalization of these complexes. Scale bar: 25 μm.

Similar articles

Cited by

References

    1. Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J Med Chem. 2005;48:1713–1716. - PubMed
    1. Erez M, Takemori AE, Portoghese PS. Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem. 1982;25:847–849. - PubMed
    1. Hruby VJ, Agnes RS, Davis P, Ma SW, Lee YS, Vanderah TW, Lai J, Porreca F. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci. 2003;73:699–704. - PMC - PubMed
    1. Faris PL, Komisaruk BR, Watkins LR, Mayer DJ. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 1983;219:310–312. - PubMed
    1. Lu L, Huang M, Liu Z, Ma L. Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats. NeuroReport. 2000;11:829–832. - PubMed

Publication types